Journal article · 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
The Lancet Oncology, 26(12), 1598–1611 · Published 25 November 2025 · DOI 10.1016/s1470-2045(25)00543-1
In brief
“Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study” is a 2025 journal article by Shukui Qin and 31 co-authors, published in The Lancet Oncology. OpenAlex counts 50 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 50
- Most cited in
- 2026 (50)
- Field-weighted impact
- 17.02
- References
- 30
- Authors
- 32
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Qin, S., Gu, S., Chan, S. L., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., Zeng, Y., . . . Vogel, A. (2025). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. The Lancet Oncology, 26(12), 1598–1611. https://doi.org/10.1016/s1470-2045(25)00543-1
MLA 9
Qin, Shukui, et al. “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.” The Lancet Oncology, vol. 26, no. 12, 2025, pp. 1598–1611. https://doi.org/10.1016/s1470-2045(25)00543-1.
Chicago
Qin, Shukui, Shanzhi Gu, Stephen Lam Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, et al. 2025. “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.” The Lancet Oncology 26 (12): 1598–1611. https://doi.org/10.1016/s1470-2045(25)00543-1.
Harvard
Qin, S. et al. (2025) ‘Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study’, The Lancet Oncology, 26(12), pp. 1598–1611. doi:10.1016/s1470-2045(25)00543-1.
IEEE
S. Qin et al., “Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study,” The Lancet Oncology, vol. 26, no. 12, pp. 1598–1611, 2025, doi: 10.1016/s1470-2045(25)00543-1.
BibTeX
@article{qin2025camrelizumab,
title = {{Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study}},
author = {Qin, Shukui and Gu, Shanzhi and Chan, Stephen Lam and Bai, Yuxian and Ren, Zhenggang and Lin, Xiaoyan and Chen, Zhendong and Jia, Weidong and Jin, Yongdong and Guo, Yabing and Hu, Xiaohua and Meng, Zhiqiang and Liang, Jun and Xiong, Jianping and Ren, Hong and Yang, Fang and Li, Wei and Chen, Yajin and Zeng, Yong and Xu, Li and Yuan, Xianglin and Li, Da and Султанбаев, А. В. and Pazgan−Simon, Monika and Pisetska, Margaryta and Melisi, Davide and Ponomarenko, Dmitriy M. and Du, Jinghua and Shi, Wei and Cheng, Ann‐Lii and others},
journal = {The Lancet Oncology},
year = {2025},
volume = {26},
number = {12},
pages = {1598--1611},
doi = {10.1016/s1470-2045(25)00543-1},
url = {https://doi.org/10.1016/s1470-2045(25)00543-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- camrelizumab
- apatinib
- sorafenib
- hepatocellular carcinoma
- unresectable liver cancer
- first-line therapy
- anti-PD-1
- VEGFR-2 inhibitors
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Qin, S., Gu, S., Chan, S. L., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., Zeng, Y., . . . Vogel, A. (2025). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. The Lancet Oncology, 26(12), 1598–1611. https://doi.org/10.1016/s1470-2045(25)00543-1
How many times has this paper been cited?
50 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Shukui Qin, Shanzhi Gu, Stephen Lam Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng and 20 more.
What is the DOI of this paper?
10.1016/s1470-2045(25)00543-1, permanently at https://doi.org/10.1016/s1470-2045(25)00543-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.